drugset / Trial / NCT06232694
Clinical Study Protocol of IAV-induced Remission Followed by Consolidation Therapy With MDCyta+Ven in ND-AML
Recruiting
54 enrolled
The First Affiliated Hospital with Nanjing Medical University
Huai'an First People's Hospital · collabYancheng First People's Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
This study evaluates the efficacy and safety of the combination of idarubicin and cytarabine induction followed by intermediate-dose cytarabine consolidation with venetoclax in the treatment of newly diagnosed adult acute myeloid leukemia (AML). This study includes the induction and consolidation phases of AML treatment.
Timeline
- Start
- 2024-01-01
- Primary completion
- 2027-12-30
- Completion
- 2027-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cytarabine | Small molecule | 100 mg/m2 | Intravenous |
| Subject | Cytarabine | Small molecule | 2000 mg/m2 | Intravenous |
| Subject | Idarubicin | Small molecule | 10 mg/m2 | Intravenous |
| Subject | Idarubicin | Small molecule | 12 mg/m2 | Intravenous |
| Subject | Venetoclax | Small molecule | 400 mg | Oral |